Home › The Medicines Company And Alnylam Form Strategic Alliance To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 For The Treatment Of Hypercholesterolemia
 

Keywords :   


The Medicines Company And Alnylam Form Strategic Alliance To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 For The Treatment Of Hypercholesterolemia

2013-02-04 07:00:00| drugdiscoveryonline News Articles

The Medicines Company and Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced recently that they have formed an exclusive global alliance for the development and commercialization of Alnylam’s ALN-PCS RNAi therapeutic program for the treatment of hypercholesterolemia

Tags: the of form company

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.07M13 Graphics invests in Landa digital press
02.07ABG helps Nordvalls increase productivity
02.07Tesla sales rise sharply after slump
02.07Hurricane Beryl Graphics
02.07Hurricane Beryl Forecast Discussion Number 16
02.07Fedrigoni teams with Progetto Quid
02.07Hurricane Beryl Forecast Advisory Number 16
02.07Hurricane Beryl Public Advisory Number 16
More »